Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives
While Alzheimer’s Disease and Multiple Sclerosis are both neurological disorders they differ in disease mechanisms, trial objectives, patient populations, and outcomes used in clinical trials. Lessons shared in the drug development journeys of both diseases can propel novel approaches leading to more effective and successful clinical trials in the quest for new treatments and better patient outcomes.
Learning from the experience of Multiple Sclerosis trials, Alzheimer’s trials can benefit from improved trial design, patient stratifications, outcome assessments, and incorporation of innovative methodologies.
In this webinar, distinguished physicians, experienced scientists, and clinical development experts, from Multiple Sclerosis and Alzheimer’s will discuss the main development challenges and how they were overcome in each respectively. This is the first-ever webinar discussing the AD vs. MS world perspective with top clinical research experts and disease area specialists.
Related Insights
Podcast
De-risking Drug Development | Episode 1: How to drive value in pre-clinical development
May 28, 2024
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Webinar
Incorporating the Patient Voice: How Patient Insights Drive Trial Design and Outcome Measures in Schizophrenia Research
Oct 30, 2024
Blog
How we can bring gene therapies to bear on diseases of aging
Jan 31, 2024
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022
Blog
Newly released FDA data and approvals signal a more welcoming regulatory environment for neuroscience clinical trials
Oct 3, 2023
Blog
Building a program for patient-guided clinical research for Alzheimer’s disease
Jan 24, 2024
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Jan 24, 2024
Blog
Improving and accelerating clinical research in dementia by integrating the patient’s voice throughout the development journey
Jan 24, 2024
Blog
Increasing trial participation and population diversity in early-phase Alzheimer’s disease drug development
Jan 24, 2024
Blog
As more neuroscience drugs are approved, the value proposition takes center stage
Feb 14, 2024
Blog
How sponsors can make it easier for rare disease patients and families to participate in trials
Feb 13, 2024
Related Insights
Podcast
De-risking Drug Development | Episode 1: How to drive value in pre-clinical development
May 28, 2024
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Webinar
Incorporating the Patient Voice: How Patient Insights Drive Trial Design and Outcome Measures in Schizophrenia Research
Oct 30, 2024
Blog
How we can bring gene therapies to bear on diseases of aging
Jan 31, 2024
Blog
New CNS Franchise Leader brings experience from pharma and as a clinician and researcher
Nov 14, 2022
Blog
Newly released FDA data and approvals signal a more welcoming regulatory environment for neuroscience clinical trials
Oct 3, 2023
Blog
Building a program for patient-guided clinical research for Alzheimer’s disease
Jan 24, 2024
Blog
Regulatory considerations in designing clinical trials for Alzheimer’s disease
Jan 24, 2024
Blog
Improving and accelerating clinical research in dementia by integrating the patient’s voice throughout the development journey
Jan 24, 2024
Blog
Increasing trial participation and population diversity in early-phase Alzheimer’s disease drug development
Jan 24, 2024
Blog
As more neuroscience drugs are approved, the value proposition takes center stage
Feb 14, 2024
Blog
How sponsors can make it easier for rare disease patients and families to participate in trials
Feb 13, 2024